• Anne C Spaulding, Cindy M Weinbaum, Daryl T-Y Lau, Richard Sterling, Leonard B Seeff, Harold S Margolis, and Jay H Hoofnagle.
• Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. aspauld@emory.edu
• Ann. Intern. Med. 2006 May 16; 144 (10): 762-9.

AbstractThe prevalence of chronic hepatitis C virus (HCV) infection in prisons ranges from 12% to 31%. There are generally accepted--albeit still evolving--guidelines for identification and treatment of hepatitis C in the community. However, there is less agreement among health professionals caring for prisoners about best practices for identification, medical management, and treatment of hepatitis C. Inmates often lack health care before incarceration. In prisons, infected persons could be identified and the management of infection initiated; however, the high prevalence of HCV infection among prisoners would impose a disproportionate cost for hepatitis C care on the correctional system. The optimal solution is for prison and public health systems in the United States to jointly provide targeted HCV testing and standard-of-care hepatitis C medical management, treatment, and prevention programs to prison inmate populations. The authors report on a January 2003 meeting of experts in prison health, public health, hepatology, and infectious diseases and explore the clinical care, prevention, and collaboration needed to provide hepatitis C management in prisoners.

22 keywords...

hide…